Evaluation of the limiting antigen avidity EIA (LAg) in people who inject drugs in Greece

This analysis assessed the utility of the limiting antigen avidity assay (LAg). Samples of people who inject drugs (PWID) in Greece with documented duration of HIV-1 infection were tested by LAg. A LAg-normalized optical density (ODn) 41·5 corresponds to a recency window period of 130 days. The prop...

Full description

Saved in:
Bibliographic Details
Published inEpidemiology and infection Vol. 145; no. 2; pp. 401 - 412
Main Authors NIKOLOPOULOS, G. K., KATSOULIDOU, A., KANTZANOU, M., ROKKA, C., TSIARA, C., SYPSA, V., PARASKEVIS, D., PSICHOGIOU, M., FRIEDMAN, S., HATZAKIS, A.
Format Journal Article
LanguageEnglish
Published England Cambridge University Press 01.01.2017
Subjects
Acquired immune deficiency syndrome
Adult
AIDS
Antibody Affinity
Antigen Avidity
Antigens
Diagnostic Errors
Drugs
Epidemics
Epidemiology
Female
Greece
HIV
HIV Antibodies - blood
HIV Infections - diagnosis
Human immunodeficiency virus
Humans
Immunoenzyme Techniques - methods
Infections
Intervention
Laboratories
Male
Research centers
RNA, Viral - blood
Substance Abuse, Intravenous - complications
Viral Load
Greece
New York
Athens Greece
Cyprus
United States > US
MED, Greece
Drug injectors
LAg
HIV
incidence
recent infection
Online AccessGet full text

Cover

Abstract This analysis assessed the utility of the limiting antigen avidity assay (LAg). Samples of people who inject drugs (PWID) in Greece with documented duration of HIV-1 infection were tested by LAg. A LAg-normalized optical density (ODn) 41·5 corresponds to a recency window period of 130 days. The proportion true recent (PTR) and proportion false recent (PFR) were estimated in 28 seroconverters and in 366 samples collected >6 months after HIV diagnosis, respectively. The association between LAg ODn and HIV RNA level was evaluated in 232 persons. The PTR was 85·7%. The PFR was 20·8% but fell to 5·9% in samples from treatment-naive individuals with long-standing infection (>1 year), and to 0 in samples with the circulating recombinant form CRF35 AD. A LAg-based algorithm with a PFR of 3·3% estimated a similar incidence trend to that calculated by analyses based on HIV-1 seroconversions. In recently infected persons indicated by LAg, the median log10 HIV RNA level was high (5·30, interquartile range 4·56–5·90). LAg can help identify highly infectious HIV(+) individuals as it accurately identifies recent infections and is correlated with the HIV RNA level. It can also produce reliable estimates of HIV-1 incidence.
AbstractList SUMMARY This analysis assessed the utility of the limiting antigen avidity assay (LAg). Samples of people who inject drugs (PWID) in Greece with documented duration of HIV-1 infection were tested by LAg. A LAg-normalized optical density (ODn) [= or <, slanted]1·5 corresponds to a recency window period of 130 days. The proportion true recent (PTR) and proportion false recent (PFR) were estimated in 28 seroconverters and in 366 samples collected >6 months after HIV diagnosis, respectively. The association between LAg ODn and HIV RNA level was evaluated in 232 persons. The PTR was 85·7%. The PFR was 20·8% but fell to 5·9% in samples from treatment-naive individuals with long-standing infection (>1 year), and to 0 in samples with the circulating recombinant form CRF35 AD. A LAg-based algorithm with a PFR of 3·3% estimated a similar incidence trend to that calculated by analyses based on HIV-1 seroconversions. In recently infected persons indicated by LAg, the median log10 HIV RNA level was high (5·30, interquartile range 4·56-5·90). LAg can help identify highly infectious HIV(+) individuals as it accurately identifies recent infections and is correlated with the HIV RNA level. It can also produce reliable estimates of HIV-1 incidence.
This analysis assessed the utility of the limiting antigen avidity assay (LAg). Samples of people who inject drugs (PWID) in Greece with documented duration of HIV-1 infection were tested by LAg. A LAg-normalized optical density (ODn) 41·5 corresponds to a recency window period of 130 days. The proportion true recent (PTR) and proportion false recent (PFR) were estimated in 28 seroconverters and in 366 samples collected >6 months after HIV diagnosis, respectively. The association between LAg ODn and HIV RNA level was evaluated in 232 persons. The PTR was 85·7%. The PFR was 20·8% but fell to 5·9% in samples from treatment-naive individuals with long-standing infection (>1 year), and to 0 in samples with the circulating recombinant form CRF35 AD. A LAg-based algorithm with a PFR of 3·3% estimated a similar incidence trend to that calculated by analyses based on HIV-1 seroconversions. In recently infected persons indicated by LAg, the median log10 HIV RNA level was high (5·30, interquartile range 4·56–5·90). LAg can help identify highly infectious HIV(+) individuals as it accurately identifies recent infections and is correlated with the HIV RNA level. It can also produce reliable estimates of HIV-1 incidence.
SUMMARY This analysis assessed the utility of the limiting antigen avidity assay (LAg). Samples of people who inject drugs (PWID) in Greece with documented duration of HIV-1 infection were tested by LAg. A LAg-normalized optical density (ODn) ⩽1·5 corresponds to a recency window period of 130 days. The proportion true recent (PTR) and proportion false recent (PFR) were estimated in 28 seroconverters and in 366 samples collected >6 months after HIV diagnosis, respectively. The association between LAg ODn and HIV RNA level was evaluated in 232 persons. The PTR was 85·7%. The PFR was 20·8% but fell to 5·9% in samples from treatment-naive individuals with long-standing infection (>1 year), and to 0 in samples with the circulating recombinant form CRF35 AD. A LAg-based algorithm with a PFR of 3·3% estimated a similar incidence trend to that calculated by analyses based on HIV-1 seroconversions. In recently infected persons indicated by LAg, the median log 10 HIV RNA level was high (5·30, interquartile range 4·56–5·90). LAg can help identify highly infectious HIV(+) individuals as it accurately identifies recent infections and is correlated with the HIV RNA level. It can also produce reliable estimates of HIV-1 incidence.
This analysis assessed the utility of the limiting antigen avidity assay (LAg). Samples of people who inject drugs (PWID) in Greece with documented duration of HIV-1 infection were tested by LAg. A LAg-normalized optical density (ODn) 1.5 corresponds to a recency window period of 130 days. The proportion true recent (PTR) and proportion false recent (PFR) were estimated in 28 seroconverters and in 366 samples collected >6 months after HIV diagnosis, respectively. The association between LAg ODn and HIV RNA level was evaluated in 232 persons. The PTR was 85.7%. The PFR was 20.8% but fell to 5.9% in samples from treatment-naive individuals with long-standing infection (>1 year), and to 0 in samples with the circulating recombinant form CRF35 AD. A LAg-based algorithm with a PFR of 3.3% estimated a similar incidence trend to that calculated by analyses based on HIV-1 seroconversions. In recently infected persons indicated by LAg, the median log sub(10) HIV RNA level was high (5.30, interquartile range 4.56-5.90). LAg can help identify highly infectious HIV(+) individuals as it accurately identifies recent infections and is correlated with the HIV RNA level. It can also produce reliable estimates of HIV-1 incidence.
This analysis assessed the utility of the limiting antigen avidity assay (LAg). Samples of people who inject drugs (PWID) in Greece with documented duration of HIV-1 infection were tested by LAg. A LAg-normalized optical density (ODn) ⩽1·5 corresponds to a recency window period of 130 days. The proportion true recent (PTR) and proportion false recent (PFR) were estimated in 28 seroconverters and in 366 samples collected >6 months after HIV diagnosis, respectively. The association between LAg ODn and HIV RNA level was evaluated in 232 persons. The PTR was 85·7%. The PFR was 20·8% but fell to 5·9% in samples from treatment-naive individuals with long-standing infection (>1 year), and to 0 in samples with the circulating recombinant form CRF35 AD. A LAg-based algorithm with a PFR of 3·3% estimated a similar incidence trend to that calculated by analyses based on HIV-1 seroconversions. In recently infected persons indicated by LAg, the median log10 HIV RNA level was high (5·30, interquartile range 4·56-5·90). LAg can help identify highly infectious HIV(+) individuals as it accurately identifies recent infections and is correlated with the HIV RNA level. It can also produce reliable estimates of HIV-1 incidence.
Author SYPSA, V.
HATZAKIS, A.
NIKOLOPOULOS, G. K.
KATSOULIDOU, A.
PARASKEVIS, D.
ROKKA, C.
TSIARA, C.
KANTZANOU, M.
PSICHOGIOU, M.
FRIEDMAN, S.
Author_xml – sequence: 1
  givenname: G. K.
  surname: NIKOLOPOULOS
  fullname: NIKOLOPOULOS, G. K.
  organization: National Development and Research Institutes (NDRI), Transmission Reduction Intervention Project (Athens site), New York, USA
– sequence: 2
  givenname: A.
  surname: KATSOULIDOU
  fullname: KATSOULIDOU, A.
  organization: Department of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece
– sequence: 3
  givenname: M.
  surname: KANTZANOU
  fullname: KANTZANOU, M.
  organization: Department of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece
– sequence: 4
  givenname: C.
  surname: ROKKA
  fullname: ROKKA, C.
  organization: Department of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece
– sequence: 5
  givenname: C.
  surname: TSIARA
  fullname: TSIARA, C.
  organization: Hellenic Centre for Disease Control and Prevention, Amarousio, Greece
– sequence: 6
  givenname: V.
  surname: SYPSA
  fullname: SYPSA, V.
  organization: Department of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece
– sequence: 7
  givenname: D.
  surname: PARASKEVIS
  fullname: PARASKEVIS, D.
  organization: Department of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece
– sequence: 8
  givenname: M.
  surname: PSICHOGIOU
  fullname: PSICHOGIOU, M.
  organization: First Department of Internal Medicine, Laiko General Hospital, University of Athens, Athens, Greece
– sequence: 9
  givenname: S.
  surname: FRIEDMAN
  fullname: FRIEDMAN, S.
  organization: National Development and Research Institutes (NDRI), New York, USA
– sequence: 10
  givenname: A.
  surname: HATZAKIS
  fullname: HATZAKIS, A.
  organization: Department of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27780490$$D View this record in MEDLINE/PubMed
BookMark eNplkEFvEzEQhS1URNPCD-AAssSlHBbGXnvtPUZVKJUicQAOnFaOd5w62tjB9rbqv8dRCkigOYxG73ujmXdBzkIMSMhrBh8YMPXxK_QSeKc16wC4YOoZWTDR9Y0Q0J-RxVFujvo5uch5BwA91-oFOedKaRA9LMiP1b2ZZlN8DDQ6Wu6QTn7viw9bakLxWwzU3PvRl0e6ul3Sq_Vy-576QA8YDxPSh7tYpx3aQsc0b_NRukmIFl-S585MGV899Uvy_dPq2_XnZv3l5vZ6uW6s4Ko0TgitR2uU5XLs0coWpeSsd-246cABWuOE1IbVQjBaO6VROiXshgvuWHtJrk57Dyn-nDGXYe-zxWkyAeOcB6Y73YqaAlT03T_oLs4p1OsqpYWULYi2UuxE2RRzTuiGQ_J7kx4HBsMx9-G_3Kvn7dPmebPH8Y_jd9AVeHMCdrnE9Ffv6q8M2vYXv-2HFA
CitedBy_id crossref_primary_10_1007_s10461_019_02402_1
crossref_primary_10_1080_10826084_2021_1914103
crossref_primary_10_3389_fmicb_2018_01825
crossref_primary_10_1111_add_15812
crossref_primary_10_3389_fpubh_2023_1277570
crossref_primary_10_1016_j_meegid_2018_04_010
crossref_primary_10_3390_pathogens12020326
crossref_primary_10_1016_j_meegid_2021_104799
crossref_primary_10_1089_aid_2020_0050
crossref_primary_10_3390_diagnostics12112657
crossref_primary_10_1080_09540121_2019_1601671
crossref_primary_10_3390_v14071587
crossref_primary_10_1002_jia2_25330
crossref_primary_10_1016_j_jve_2022_100085
Cites_doi 10.1089/aid.2011.0258
10.1097/QAI.0000000000000006
10.1371/journal.pone.0114947
10.1089/aid.2013.0113
10.1097/QAD.0000000000000307
10.1016/S0140-6736(11)60842-8
10.1371/journal.pone.0033328
10.1093/infdis/jis661
10.1111/add.12999
10.3109/10826084.2015.978659
10.1097/QAD.0000000000000221
10.1089/aid.2009.0133
10.1371/journal.pone.0098038
10.1093/infdis/jis659
10.1097/QAD.0000000000000429
10.2807/ese.13.36.18966-en
10.1089/088922202753472874
10.1128/JCM.42.6.2623-2628.2004
10.1097/00126334-200304010-00012
10.1089/aid.2010.0159
10.1093/aje/kws436
10.1016/j.meegid.2015.08.004
10.1097/EDE.0b013e3182576c07
10.1097/QAD.0b013e32801481b7
10.1371/journal.pone.0133255
10.1016/S1473-3099(09)70300-7
10.1093/epirev/mxq002
10.1371/journal.pone.0078941
10.1097/QAD.0b013e3281532c82
10.1097/QAI.0b013e3182986fdf
10.1001/jama.300.5.520
10.1089/aid.2015.0097
10.1371/journal.pone.0082772
10.1093/infdis/jis658
10.1089/aid.2013.0055
10.1089/088922203766774522
10.1371/journal.pone.0064201
10.1007/s10461-013-0643-5
10.1097/QAD.0000000000000135
10.1097/00002030-200309050-00005
10.1089/aid.2014.0081
10.1038/nri2674
10.1089/aid.2013.0169
ContentType Journal Article
Copyright Cambridge University Press 2016
Copyright © Cambridge University Press 2016
Copyright_xml – notice: Cambridge University Press 2016
– notice: Copyright © Cambridge University Press 2016
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7QL
7RV
7T2
7U9
7X7
7XB
88A
88E
8C1
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AN0
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
KB0
LK8
M0S
M1P
M7N
M7P
NAPCQ
PQEST
PQQKQ
PQUKI
PRINS
7U2
DOI 10.1017/S0950268816002417
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Nursing & Allied Health Database
Health and Safety Science Abstracts (Full archive)
Virology and AIDS Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
British Nursing Database
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Nursing & Allied Health Premium
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Safety Science and Risk
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Collection
AIDS and Cancer Research Abstracts
Health & Safety Science Abstracts
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest Central (Alumni)
Safety Science and Risk
DatabaseTitleList ProQuest Central Student

CrossRef
Health & Safety Science Abstracts
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
Biology
EISSN 1469-4409
EndPage 412
ExternalDocumentID 4321479003
10_1017_S0950268816002417
27780490
26521103
Genre Evaluation Study
Journal Article
GeographicLocations Greece
New York
Athens Greece
Cyprus
United States--US
MED, Greece
GeographicLocations_xml – name: Greece
– name: New York
– name: Athens Greece
– name: Cyprus
– name: United States--US
– name: MED, Greece
GrantInformation_xml – fundername: NIDA NIH HHS
  grantid: DP1 DA034989
– fundername: NIDA NIH HHS
  grantid: P30 DA011041
GroupedDBID ---
-E.
-~X
..I
.FH
09C
09E
0E1
0R~
29G
3V.
4.4
5GY
5VS
6PF
74X
74Y
7RV
7X7
7~V
88A
88E
8C1
8FE
8FH
8FI
8FJ
8R4
8R5
AAAZR
AABES
AABWE
AACGO
AACJH
AAEED
AAGFV
AAKTX
AAMNQ
AANCE
AARAB
AASVR
AATID
AAUIS
AAUKB
AAWTL
ABBHK
ABBXD
ABFBI
ABITZ
ABKKG
ABKMT
ABLJU
ABMWE
ABOCM
ABPLY
ABQTM
ABQWD
ABROB
ABTCQ
ABTLG
ABUWG
ABWCF
ABXSQ
ABZCX
ACBEK
ACBMC
ACCHT
ACGFS
ACIMK
ACPRK
ACQFJ
ACREK
ACUIJ
ACUYZ
ACWGA
ACZBM
ACZUX
ACZWT
ADAZD
ADBBV
ADDNB
ADFEC
ADGEJ
ADKIL
ADOCW
ADVJH
ADZLD
AEBAK
AEBPU
AEHGV
AEMTW
AENEX
AENGE
AEUPB
AEXZC
AEYHU
AEYYC
AFFUJ
AFKQG
AFKRA
AFKSM
AFLOS
AFLVW
AFRAH
AFRIC
AFUTZ
AGABE
AGJUD
AGOOT
AHIPN
AHLTW
AHMBA
AHQXX
AHRGI
AIGNW
AIHIV
AIOIP
AISIE
AJ7
AJCYY
AJPFC
AJQAS
ALMA_UNASSIGNED_HOLDINGS
ALVPG
ALWZO
AN0
ANPSP
AOIJS
AQJOH
AQVQM
ARABE
ATUCA
AUXHV
AZGZS
BBLKV
BBNVY
BENPR
BGHMG
BHPHI
BKEYQ
BLZWO
BMAJL
BNQBC
BPHCQ
BRIRG
BVXVI
C0O
CBIIA
CCPQU
CFAFE
CHEAL
CJCSC
CS3
DCCCD
DNJUQ
DOHLZ
DOOOF
DU5
DWIUU
EBS
EJD
EMOBN
EX3
F5P
FYUFA
GROUPED_DOAJ
HCIFZ
HG-
HMCUK
HST
HYE
HZ~
I.6
IKXGN
IOEEP
IOO
IPYYG
IS6
I~P
J36
J38
J3A
JAAYA
JBMMH
JENOY
JHFFW
JHPGK
JKPOH
JKQEH
JLS
JLXEF
JPM
JQKCU
JSG
JSODD
JST
JVRFK
KCGVB
KFECR
L7B
L98
LK8
LW7
M-V
M0L
M1P
M7P
M7~
NAPCQ
NIKVX
O9-
OK1
OVD
OYBOY
P2P
PQQKQ
PROAC
PSQYO
Q2X
RAMDC
RCA
ROL
RPM
RR0
S6-
S6U
SA0
SAAAG
SY4
T9M
TEORI
UCJ
UKHRP
UT1
UU6
WFFJZ
WH7
WOW
WQ3
WXU
WXY
WYP
ZYDXJ
~02
-1D
-1F
-2P
-2V
-~6
-~N
.GJ
3O-
53G
6~7
9M5
AAGKA
AAKDD
AANRG
ABVFV
ABVZP
ABXAU
ABZUI
ACETC
ACMRT
ADACV
ADOVH
ADOVT
ADULT
AENCP
AFFNX
AGLWM
AKZCZ
ALIPV
ARZZG
AYIQA
BCGOX
BESQT
BJBOZ
BQFHP
CAG
CCQAD
CCUQV
CDIZJ
CFBFF
CGQII
CGR
COF
CTKSN
CUY
CVF
ECM
EGQIC
EIF
HGD
HQ3
HTVGU
I.7
I.9
IPSME
KAFGG
LHUNA
M48
M8.
NMFBF
NPM
NZEOI
RIG
ZDLDU
ZGI
ZJOSE
ZMEZD
ZXP
~V1
AAYXX
CITATION
KC5
7QL
7T2
7U9
7XB
8FK
AFPKN
AZQEC
C1K
DWQXO
GNUQQ
H94
K9.
M7N
PQEST
PQUKI
PRINS
7U2
ID FETCH-LOGICAL-c427t-f4488dca7c25d9ec53e55219f3db60f0ecaf458a1a1ae0a88f78e5f74cb242f13
IEDL.DBID 7X7
ISSN 0950-2688
IngestDate Fri Oct 25 09:26:58 EDT 2024
Mon Nov 04 10:45:27 EST 2024
Thu Sep 26 16:27:51 EDT 2024
Wed Oct 16 00:45:54 EDT 2024
Fri Feb 02 07:18:35 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Drug injectors
LAg
HIV
incidence
recent infection
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c427t-f4488dca7c25d9ec53e55219f3db60f0ecaf458a1a1ae0a88f78e5f74cb242f13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.cambridge.org/core/services/aop-cambridge-core/content/view/C5930049573C923B48879F881312DDFD/S0950268816002417a.pdf/div-class-title-evaluation-of-the-limiting-antigen-avidity-eia-lag-in-people-who-inject-drugs-in-greece-div.pdf
PMID 27780490
PQID 1884553043
PQPubID 6286
PageCount 12
ParticipantIDs proquest_miscellaneous_1868342680
proquest_journals_1884553043
crossref_primary_10_1017_S0950268816002417
pubmed_primary_27780490
jstor_primary_26521103
PublicationCentury 2000
PublicationDate 20170101
2017-01-00
PublicationDateYYYYMMDD 2017-01-01
PublicationDate_xml – month: 1
  year: 2017
  text: 20170101
  day: 1
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Cambridge
PublicationTitle Epidemiology and infection
PublicationTitleAlternate Epidemiol Infect
PublicationYear 2017
Publisher Cambridge University Press
Publisher_xml – name: Cambridge University Press
References Murphy (S0950268816002417_ref6) 2008; 13
S0950268816002417_ref38
S0950268816002417_ref37
S0950268816002417_ref39
S0950268816002417_ref45
S0950268816002417_ref44
S0950268816002417_ref47
S0950268816002417_ref46
S0950268816002417_ref41
S0950268816002417_ref40
S0950268816002417_ref43
S0950268816002417_ref42
Longosz (S0950268816002417_ref33) 2014; 22
S0950268816002417_ref49
S0950268816002417_ref48
S0950268816002417_ref12
S0950268816002417_ref11
S0950268816002417_ref14
S0950268816002417_ref13
S0950268816002417_ref51
S0950268816002417_ref10
S0950268816002417_ref3
S0950268816002417_ref1
S0950268816002417_ref7
S0950268816002417_ref19
S0950268816002417_ref5
S0950268816002417_ref4
S0950268816002417_ref16
Rottinghaus (S0950268816002417_ref50) 2014; 22
S0950268816002417_ref15
S0950268816002417_ref9
S0950268816002417_ref18
S0950268816002417_ref8
S0950268816002417_ref17
S0950268816002417_ref23
S0950268816002417_ref22
S0950268816002417_ref25
S0950268816002417_ref24
S0950268816002417_ref21
S0950268816002417_ref20
Mastro (S0950268816002417_ref2) 2010; 2
S0950268816002417_ref27
S0950268816002417_ref26
S0950268816002417_ref29
S0950268816002417_ref28
S0950268816002417_ref34
S0950268816002417_ref36
S0950268816002417_ref35
S0950268816002417_ref30
S0950268816002417_ref32
S0950268816002417_ref31
References_xml – ident: S0950268816002417_ref37
  doi: 10.1089/aid.2011.0258
– ident: S0950268816002417_ref36
  doi: 10.1097/QAI.0000000000000006
– ident: S0950268816002417_ref24
– ident: S0950268816002417_ref14
  doi: 10.1371/journal.pone.0114947
– ident: S0950268816002417_ref23
  doi: 10.1089/aid.2013.0113
– ident: S0950268816002417_ref1
  doi: 10.1097/QAD.0000000000000307
– ident: S0950268816002417_ref49
  doi: 10.1016/S0140-6736(11)60842-8
– ident: S0950268816002417_ref12
  doi: 10.1371/journal.pone.0033328
– ident: S0950268816002417_ref3
  doi: 10.1093/infdis/jis661
– ident: S0950268816002417_ref17
  doi: 10.1111/add.12999
– ident: S0950268816002417_ref16
  doi: 10.3109/10826084.2015.978659
– ident: S0950268816002417_ref40
  doi: 10.1097/QAD.0000000000000221
– ident: S0950268816002417_ref13
  doi: 10.1089/aid.2009.0133
– ident: S0950268816002417_ref30
  doi: 10.1371/journal.pone.0098038
– ident: S0950268816002417_ref41
  doi: 10.1093/infdis/jis659
– ident: S0950268816002417_ref34
  doi: 10.1097/QAD.0000000000000429
– volume: 13
  start-page: 18966
  year: 2008
  ident: S0950268816002417_ref6
  article-title: Assays for the detection of recent infections with human immunodeficiency virus type 1
  publication-title: Eurosurveillance
  doi: 10.2807/ese.13.36.18966-en
  contributor:
    fullname: Murphy
– ident: S0950268816002417_ref7
  doi: 10.1089/088922202753472874
– ident: S0950268816002417_ref5
– volume: 22
  start-page: 531
  year: 2014
  ident: S0950268816002417_ref50
  article-title: Performance of the limiting-antigen avidity EIA for use with dried blood spot specimens [Abstract]
  publication-title: Topics in Antiviral Medicine
  contributor:
    fullname: Rottinghaus
– ident: S0950268816002417_ref8
  doi: 10.1128/JCM.42.6.2623-2628.2004
– volume: 2
  start-page: 1
  year: 2010
  ident: S0950268816002417_ref2
  article-title: Estimating HIV incidence in populations using tests for recent infection: issues, challenges and the way forward
  publication-title: Journal of HIV/AIDS Surveillance and Epidemiology
  contributor:
    fullname: Mastro
– ident: S0950268816002417_ref11
  doi: 10.1097/00126334-200304010-00012
– ident: S0950268816002417_ref29
  doi: 10.1089/aid.2010.0159
– ident: S0950268816002417_ref39
  doi: 10.1093/aje/kws436
– ident: S0950268816002417_ref51
– ident: S0950268816002417_ref45
– ident: S0950268816002417_ref19
  doi: 10.1016/j.meegid.2015.08.004
– volume: 22
  start-page: 532
  year: 2014
  ident: S0950268816002417_ref33
  article-title: The Impact of HIV Subtype On Specificity of Cross-Sectional HIV Incidence Assays in Rakai, Uganda [Abstract]
  publication-title: Topics in Antiviral Medicine
  contributor:
    fullname: Longosz
– ident: S0950268816002417_ref22
  doi: 10.1097/EDE.0b013e3182576c07
– ident: S0950268816002417_ref26
  doi: 10.1097/QAD.0b013e32801481b7
– ident: S0950268816002417_ref46
  doi: 10.1371/journal.pone.0133255
– ident: S0950268816002417_ref27
  doi: 10.1016/S1473-3099(09)70300-7
– ident: S0950268816002417_ref4
  doi: 10.1093/epirev/mxq002
– ident: S0950268816002417_ref15
  doi: 10.1371/journal.pone.0078941
– ident: S0950268816002417_ref47
  doi: 10.1097/QAD.0b013e3281532c82
– ident: S0950268816002417_ref28
  doi: 10.1097/QAI.0b013e3182986fdf
– ident: S0950268816002417_ref10
  doi: 10.1001/jama.300.5.520
– ident: S0950268816002417_ref35
  doi: 10.1089/aid.2015.0097
– ident: S0950268816002417_ref38
  doi: 10.1371/journal.pone.0082772
– ident: S0950268816002417_ref42
  doi: 10.1093/infdis/jis658
– ident: S0950268816002417_ref44
  doi: 10.1089/aid.2013.0055
– ident: S0950268816002417_ref9
  doi: 10.1089/088922203766774522
– ident: S0950268816002417_ref43
  doi: 10.1371/journal.pone.0064201
– ident: S0950268816002417_ref18
  doi: 10.1007/s10461-013-0643-5
– ident: S0950268816002417_ref25
– ident: S0950268816002417_ref48
  doi: 10.1097/QAD.0000000000000135
– ident: S0950268816002417_ref20
  doi: 10.1097/00002030-200309050-00005
– ident: S0950268816002417_ref31
  doi: 10.1089/aid.2014.0081
– ident: S0950268816002417_ref21
  doi: 10.1038/nri2674
– ident: S0950268816002417_ref32
  doi: 10.1089/aid.2013.0169
SSID ssj0009287
Score 2.3169293
Snippet This analysis assessed the utility of the limiting antigen avidity assay (LAg). Samples of people who inject drugs (PWID) in Greece with documented duration of...
SUMMARY This analysis assessed the utility of the limiting antigen avidity assay (LAg). Samples of people who inject drugs (PWID) in Greece with documented...
SUMMARY This analysis assessed the utility of the limiting antigen avidity assay (LAg). Samples of people who inject drugs (PWID) in Greece with documented...
SourceID proquest
crossref
pubmed
jstor
SourceType Aggregation Database
Index Database
Publisher
StartPage 401
SubjectTerms Acquired immune deficiency syndrome
Adult
AIDS
Antibody Affinity
Antigen Avidity
Antigens
Diagnostic Errors
Drugs
Epidemics
Epidemiology
Female
Greece
HIV
HIV Antibodies - blood
HIV Infections - diagnosis
Human immunodeficiency virus
Humans
Immunoenzyme Techniques - methods
Infections
Intervention
Laboratories
Male
Research centers
RNA, Viral - blood
Substance Abuse, Intravenous - complications
Viral Load
Title Evaluation of the limiting antigen avidity EIA (LAg) in people who inject drugs in Greece
URI https://www.jstor.org/stable/26521103
https://www.ncbi.nlm.nih.gov/pubmed/27780490
https://www.proquest.com/docview/1884553043
https://search.proquest.com/docview/1868342680
Volume 145
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEB_0DkEQ0dPT6nlE8EGFYNOm6fRJ1mOPU-QQ8WB9Kmk-TkHa83YX8b93punuPogSKDQJeZh8zC8zv8wAvDDWRKy0l43zUeoQUdrCekm3C-Wb2KFNbItzc3ahPyyqxWRwW060ys2ZOB7UfnBsI3-jEDWnuNHl26ufkrNGsXd1SqFxE_ZVkRumdNWLehd0txgT5BGKyGVhEDdezTFkNFVynWLHlB7zle30UqIm_ht0jsrn9B7cnVCjmKVpvg83Qn8At1Ieyd8HcCcZ30R6U_QAvs63MbzFEAVhPPGDHzKRmhIkSQ7AKZjLTghczN_PxMuPs8tX4nsvEp9c_Po20B9baIS_Xl8uuYkJOi48hIvT-ZeTMznlUJBOF_VKRrp-oXe2dkXlm-CqMlSksZtY-s7kMQ_ORl2hVVRCbhFjjaGKtXYdKe-oykPY64c-PAZhjVWld5HOT6upNIjOdaYxynBIG53B640E26sUKqNNHLK6_UvcGRyOMt72LEzFd9Eyg6ON0NtpOy3b3eRn8HzbTBuBvRu2D8Oa-xgsCW9gnsGjNFm7wWuOs9TkT_4_-FO4XbDWHi0sR7C3ul6HZ4Q5Vt3xuLDoiyfqGPbfzc8_ff4D5y3Sug
link.rule.ids 315,783,787,12068,12235,21400,27936,27937,31731,31732,33278,33279,33756,33757,43322,43591,43817,74073,74342,74630
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dSxwxEB9aS6kgpWrVVVtT6IMtBPcjm80-laOcnO3VJ4Xr05LNhwqyq94d4n_vzGbv7kFa8rRJyMPMJjOZmfx-AF-lll7lwvLSWM-F84rrVFuOt4vElr5WOlRbnMvRpfg1ySd9wG3al1UuzsTuoLatoRj5SaKUIIobkf24u-fEGkXZ1Z5C4zW8IRwuYjAoJsUKdDftCPLQi4h5KpVaZDU7yGjspL6EElOi4ytb2aVQmvhvp7MzPqcf4H3vNbJBUPMmvHLNFrwNPJJPW7ARgm8svCnahr_DJYY3az1DH4_d0kMmNFMMJUkAnIxq2dEDZ8OzATseD66-sZuGhXpy9njd4hdFaJh9mF9NaYgKdIz7CJenw4ufI95zKHAj0mLGPV6_lDW6MGluS2fyzOVosUuf2VrGPnZGe5ErnWBzsVbKF8rlvhCmRuPtk2wH1pq2cXvAtNRJZo3H81MLbKVSxtSylIkkSBsRwfeFBKu7AJVRhRqyonoh7gh2OhkvZ6Yyp7toFsHhQuhVv52m1Ur5EXxZDuNGoOyGblw7pzlSZehvqDiC3aCs1eIF4SyV8f7_Fz-Cd6OLP-NqfHb--wDWU7LgXbTlENZmD3P3Cf2PWf25-8meAVOA0zo
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEB_0ilIoRau1W6tG8MEWQvcjm80-lVPvaLUcRSy0T0s2H7VQdtveHdL_3pnN3t1DUfKUD_Iw-ZjJzC_zA_gktfQqF5aXxnounFdcp9pyfF0ktvS10gFtMZHH5-L7RX7R45-mPaxycSd2F7VtDfnIDxOlBFHciOzQ97CIs2_jo9s7TgxSFGnt6TSewlohZBYPYO3LaHL2c5WCN-3o8tCmiHkqlVrEOLsE0thIbQmFqUTHXrbSUgGo-G8TtFNF4xew2duQbBgW_SU8cc0WPAuskg9bsBFccSz8MHoFl6NlRm_WeoYWH7uhb02otBjKldJxMkK2oz3ORidD9vl0eLXPrhsW0OXsz-8Wa-SvYfZ-fjWlLoLrGPcazsejX1-Pec-owI1Iixn3-BhT1ujCpLktnckzl6P-Ln1maxn72BntRa50gsXFWilfKJf7QpgaVblPsm0YNG3jdoBpqZPMGo-3qRZYSqWMqWUpE0kJbkQEBwsJVrchcUYVEGVF9UjcEWx3Ml6OTGVOL9Msgr2F0Kv-cE2r1VaI4OOyG48FxTp049o5jZEqQ-tDxRG8CYu1mrygrEtlvPv_yT_Ac9xh1enJ5MdbWE9JnXeulz0YzO7n7h0aI7P6fb_L_gIjhtjX
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+the+limiting+antigen+avidity+EIA+%28LAg%29+in+people+who+inject+drugs+in+Greece&rft.jtitle=Epidemiology+and+infection&rft.au=NIKOLOPOULOS%2C+G.+K.&rft.au=KATSOULIDOU%2C+A.&rft.au=KANTZANOU%2C+M.&rft.au=ROKKA%2C+C.&rft.date=2017-01-01&rft.pub=Cambridge+University+Press&rft.issn=0950-2688&rft.eissn=1469-4409&rft.volume=145&rft.issue=2&rft.spage=401&rft.epage=412&rft_id=info:doi/10.1017%2FS0950268816002417&rft.externalDocID=26521103
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0950-2688&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0950-2688&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0950-2688&client=summon